A
Aminah Jatoi
Researcher at Mayo Clinic
Publications - 440
Citations - 15796
Aminah Jatoi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 46, co-authored 404 publications receiving 12708 citations. Previous affiliations of Aminah Jatoi include University of Texas Health Science Center at San Antonio & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527
Rachel A. Freedman,Jared C. Foster,Drew K. Seisler,Jacqueline Lafky,Hyman B. Muss,Harvey J. Cohen,Jeanne S. Mandelblatt,Eric P. Winer,Clifford A. Hudis,Ann H. Partridge,Lisa A. Carey,C. Cirrincione,Alvaro Moreno-Aspitia,Gretchen Kimmick,Aminah Jatoi,Arti Hurria +15 more
TL;DR: Older patients with breast cancer remain largely underrepresented in cooperative group therapeutic trials and novel strategies to increase accrual of older patients are critical to meaningfully change the evidence base for this growing patient population.
Journal ArticleDOI
Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer.
Andrea L. Cheville,Paul J. Novotny,Jeff A. Sloan,Jeffrey R. Basford,Jason A. Wampfler,Yolanda I. Garces,Aminah Jatoi,Ping Yang +7 more
TL;DR: A single SxCl comprising dyspnea, fatigue, and cough has a stable prevalence among LC survivors up to five years after diagnosis but is not stable among individuals.
Journal ArticleDOI
Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)
Aminah Jatoi,Abby R. Thrower,Jeff A. Sloan,Patrick J. Flynn,Nicole Lea Wentworth-Hartung,Shaker R. Dakhil,Bassam I. Mattar,Daniel A. Nikcevich,Paul J. Novotny,Aleksandar Sekulic,Charles L. Loprinzi +10 more
TL;DR: Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash and quality of life scores declined but remained comparable between arms.
Journal ArticleDOI
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
Aminah Jatoi,Steven E. Schild,Nathan R. Foster,G. Henning,K. J. Dornfeld,Patrick J. Flynn,Tom R. Fitch,S. R. Dakhil,Kendrith M. Rowland,P. J. Stella,Gamini S. Soori,A. A. Adjei +11 more
TL;DR: This combination of cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC exceeds the anticipated survival rate, and merits further study.
Journal ArticleDOI
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
TL;DR: With appropriate treatment, the dermatologic toxicities associated with anti‐EGFR monoclonal antibody therapy can be managed, minimizing patient discomfort and the need for therapy interruption and/or discontinuation, and preemptive treatment can reduce dermatologic toxicity severity.